HOME
ABOUT US
OUR ISSUES
Federal Budget
Information & Access
Nonprofit Advocacy
Regulatory Policy
DudleyWatch
Unmet Needs
Paralysis by Analysis
White House Interventions
Special Interests v. Public Interest
National Solutions for National Needs
In Congress
In the Courts
Public Participation
The Bush Record
Reports & Analyses
RegWatch
Resource Center
PRESS ROOM
ACTION CENTER
PUBLICATIONS
THE WATCHER
OUR BLOGS
SIGN UP
Receive news, updates, and alerts!
DONATE
Help support our work
OTHER SITES
FedSpending.org
RTK NET
NPAction
Working Group on Community Right-to-Know
Citizens for Sensible Safeguards
Open the Government
"[P]eople acting in a group can accomplish things which no individual acting alone could even hope to bring about." - FDR
News & Analysis | REG•WATCH Blog | Press Room
Monday, April 14, 2008
An editorial in today's New York Times condemns a policy, known as preemption, which prohibits consumers from suing manufacturers if a product harms a consumer, so long as that product is in some way regulated by the federal government. The editorial calls preemption a "perverse legal doctrine" and warns that as it "continues to spread, the public will be deprived of a vital tool for policing companies and unearthing documents that reveal their machinations."
Federal agencies are responsible for enforcing the positive law enacted by Congress. However, even when positive laws and regulations work, citizens must have an opportunity to seek legal redress if a product causes harm. Tort law provides that opportunity by allowing citizens to seek damages from the makers of those products.
A Times investigation into the birth control patch Ortho Evra proves why positive law sometimes does not work, and why tort law must be preserved:
For years, Johnson & Johnson obscured evidence that its popular Ortho Evra birth control patch delivered much more estrogen than standard birth control pills, potentially increasing the risk of blood clots and strokes, according to internal company documents. But because the Food and Drug Administration approved the patch, the company is arguing in court that it cannot be sued by women who claim that they were injured by the product — even though its old label inaccurately described the amount of estrogen it released.
In their attempts to shirk accountability by erasing the possibility of tort claims, pharmaceutical companies and other industries have found a friend in the Bush administration. The administration has advanced a pro-preemption argument in a number of policy areas covering everything from cars to mattresses.
According to a recent paper from the Center for Progressive Reform, the administration has been fighting for preemption on two fronts. "One form has been to intervene on the side of industry in tort litigation by the filing of amicus briefs arguing that the plaintiff 's claims against the corporate defendant are preempted by the agency's regulations or its general authority over the health or safety matters at issue," the paper argues.
The Bush administration has also tried, and been largely successful, in writing regulations that expressly preempt tort law, according to the paper. Federal agencies, including the FDA and the Consumer Product Safety Commission, have inserted preemption language into the preamble of regulations.
Under Bush, agencies have been inserting the language at the last minute, after the public comment period has closed. In the case of an FDA regulation on drug labels, "FDA deprived most of the public — including state officials, Congress members, and interested individuals and citizen groups — of any chance to weigh in on the matter before the rule was finalized."
Wednesday, April 09, 2008
Ruth Marcus has written a great op-ed in today's Washington Post. Marcus discusses recently-discovered lapses in the FAA's aircraft inspection program and connects it to the broader pattern of anti-regulatory policies in the Bush administration:
The lapses are symptomatic, too, of much deeper problems across the government. These are not outbreaks of sheer, "heck of a job" incompetence. There is some of that, certainly, but this administration's allergy to government intervention and affection for the private sector have contributed to a spate of regulatory failures, from lead in imported toys to dangerous prescription drugs to subprime mortgages. The course of these events traces a depressingly familiar arc: paeans to the free market followed by disaster followed by grudging acceptance of regulation. Just a year ago, Treasury Undersecretary Robert Steel proclaimed that new regulation of financial markets was unnecessary because "sophisticated financial firms have both the direct financial incentives and expertise to provide for effective market discipline." Right. Just ask Bear Stearns.
Check it out here: "When a Watchdog Isn't"
Latest Entries by Theme
All Themes
Enforcement
About This Blog
Rollbacks
Safety
Industry Influence
Cost-Benefit Analysis
Publications
Consumer Issues
Environment
Public Health
Oversight
In the White House
Most Recent Entries for RegWatch
Bush Administration Politicos Will Stick Around
Rules of the Road: DOT Puts Truck Drivers and Motorists at Risk
Last-Minute Rule Allows More Dirty Oil Production
Recommendations on Regulatory Reform for the Next President and Congress
Bush Handing over Wilderness to Oil and Gas Industry
New Rule Likely to Cut Health Care for the Poor
For High Court, High Stakes Case on Preemption
Watching out for Midnight Regulations
FDA Experts Fought Rule to Protect Drug Makers
Science Advisors Chide FDA on Plastics Chemical
Archived Entries for Publications
July
June
May
April
March
February
January
December, 2007
November, 2007
October, 2007
August, 2007
April, 2007
March, 2007
February, 2007
December, 2006
October, 2006
September, 2006
August, 2006
July, 2006
June, 2006
May, 2006
April, 2006
March, 2006
February, 2006
January, 2006
December, 2005
November, 2005
October, 2005
September, 2005
August, 2005
July, 2005
June, 2005
May, 2005
April, 2005
March, 2005
February, 2005
January, 2005
December, 2004
November, 2004
October, 2004
September, 2004